- €13.00bn
- €12.43bn
- €3.93bn
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients
Brief: Ipsen Initiates A New Share Buy-Back Program
Brief: FDA Alerts Health Care Providers, Patients On Increased Risk Of New Blood Cancers With Tazverik Use
France's Ipsen Q1 revenue rises 17%, rare disease sales more than double
Brief: Ipsen Confirms 2026 Guidance
Brief: Ipsen: EC Conditional Marketing Authorization For Ojemda (Tovorafenib)
Brief: Ipsen Says Beech Tree Obtained French Regulator Exemption On Public Tender Offer
Europe Research Roundup: HBX Group, Ipsen, Knorr Bremse
Brief: Ipsen Appoints Michelle C. Werner As EVP, President Of North America
Brief: HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Ipsen shares slip after cancer drug Tazverik withdrawal
Brief: Ipsen Withdraws Tazverik® (tazemetostat) In Follicular Lymphoma, Epithelioid Sarcoma
Brief: Ipsen Receives Positive CHMP Opinion For Ojemda
Ipsen shares rise driven by FY results beat
France's Ipsen FY 2025 revenue misses expectations
Brief: Ipsen FY Revenue EUR 3,675.9 Million